Secondary Logo

Journal Logo

Review article

The pneumatic tourniquet: mechanical, ischaemia–reperfusion and systemic effects

Estebe, Jean-Pierre; Davies, Joanna M; Richebe, Philippe

Author Information
European Journal of Anaesthesiology: June 2011 - Volume 28 - Issue 6 - p 404-411
doi: 10.1097/EJA.0b013e328346d5a9

Abstract

Introduction

The first recorded use of a tourniquet was by a Roman surgeon in the second century AD. In 1817, a French surgeon, Jean-Louis Petit, described his device for haemostasis, which he named the ‘tourniquet’. The pneumatic tourniquet was introduced by Harvey Cushing in 1904 as an adjunct for surgery on the extremities. It is widely used to achieve relatively bloodless surgery, improve the identification of vital structures and expedite surgical procedures. Tourniquets are also used in combat and civilian emergency settings.

Patient safety has been improved and complications reduced by the development of wide, contoured and electronically controlled pneumatic cuffs. Despite this, tissue injury by compression under the pneumatic tourniquet cuff, and ischaemia–reperfusion injuries still occur. The combination of these different mechanical, ischaemia–reperfusion and systemic effects could explain the prolonged hospitalisation time and delayed return to work observed in tourniquet versus non-tourniquet groups.1–3

We have previously reviewed the effects of tourniquet use in orthopaedic surgery.4,5 Based on human and experimental studies published since 2000, this review describes the impact of mechanical, ischaemia–reperfusion and systemic effects of the pneumatic tourniquet, new techniques to minimise these effects and some of the proposed treatments for tourniquet-induced injury. We searched the MEDLINE database for studies using the term ‘pneumatic tourniquet’. All full-text randomised and non-randomised, controlled trials, case reports, letters, and guidelines were included.

Mechanical effects

Mechanical effects are those caused by direct compression of structures underneath the inflated tourniquet cuff. Use of correctly fitted and placed tourniquet cuffs with inflation pressures kept to a minimum reduces the potentially damaging impact of this compression.

Limb exsanguination

Limb exsanguination before tourniquet inflation is usually accomplished by mechanical means such as an Esmarch bandage, Rhys-Davies exsanguinator or crepe bandage. Aggressive exsanguination with any device increases the risk of disseminating tumour cells or infection and dislodgement of deep venous thromboses (DVTs) resulting in potentially fatal pulmonary emboli.6 Exsanguination of the limb by elevation alone is a slightly less effective, but is a safe and easy procedure. It permits better visualisation of superficial vessels compared with complete exsanguination, allowing better haemostasis.7 To achieve maximum exsanguination, it is recommended to elevate the arm at 90° for 5 min and elevate the leg at 45° for 5 min, without arterial compression, while the limb is surgically prepared and draped. If the pneumatic tourniquet is effective in occluding the extraosseous blood supply, some intraosseous blood supply is retained, which can make it difficult to obtain a completely bloodless field.8

Pressure under tourniquet

Skin, muscles, nerves and vessels may be damaged by the mechanical pressure of the tourniquet, as a result of sagittal forces causing compression, and axial forces causing stretching, due to the uneven distribution of pressure under the cuff (see Fig. 1).

Fig. 1
Fig. 1

Instead of using an arbitrary pressure (100–150 and 50–75 mmHg above systolic pressure for the lower and upper limbs, respectively),9 the minimal arterial occlusion pressure (AOP) should be determined before tourniquet application in order to minimise tissue injury.10 The AOP depends on the size of the tourniquet used.11 Graham's formula states:

AOP = [(systolic pressure−diastolic pressure) (limb circumference)/3(cuff width)] + diastolic pressure.12

The tourniquet pressure is then set at AOP and 50–75 mmHg. Using this formula, the tourniquet pressure can be decreased by 20–40% in adults11 and by more than 50% in children,13 compared with the arbitrary pressures often used. The tourniquet pressure must be adjusted during surgery relative to blood pressure. Recently, a new device has been introduced that synchronises the non-invasive blood pressure with the tourniquet pressure.14

If the AOP is not determined (as above), the tourniquet pressure used should be set at 75–100 mmHg above systolic arterial pressure.15 A pressure that occludes venous but not arterial blood flow can induce venous congestion, which is easily recognised during surgery. Calcified, non-compressible arteries may also cause tourniquet failure. The mass of tissue affected by the tourniquet is greater in the leg than in the arm. The tourniquet is usually applied at the most proximal part of the extremity, but placing it as distally as surgery allows (forearm, wrist, calf and forefoot) minimises the mass of tissue affected. A tourniquet at the calf must be positioned 3–4 cm below the fibular head (mid calf) to avoid injury to the common peroneal nerve.

The shape of the tourniquet is critical. A contoured rather than a straight tourniquet should be used for conical shaped limbs to minimise excessive pressure on one edge of the cuff, particularly in obese or very muscular patients (see Fig. 1). A wide or contoured cuff achieves haemostasis at lower inflation pressures than a narrow cuff and is painless when pressure is limited to the lowest effective level.16,17 Despite a possible risk of increased nerve injury, the widest curved cuff appropriate to the size of the extremity must be chosen (that is, wider than half the limb's diameter: >5 cm for the upper and >9 cm for the lower limb); the cuff should overlap by at least 7 cm but no more than 15 cm and must be connected to an integrated cuff inflation system.11,17–19

Tissue injury

Skin

Wrinkle-free padding beneath the tourniquet is essential for reducing skin damage due to shearing stresses.20 To avoid chemical burns beneath the tourniquet, it must be separated from the operative field with a self-adhesive plastic drape before skin preparation.21,22 The tourniquet cuff should not be rotated to a new position after it has been inflated, as shearing forces may damage underlying tissues.

Muscle

It has been clearly demonstrated in both animal and human studies that compression injury due to the tourniquet results in a more significant loss of muscle functional strength, contractile speed and fatigability than tourniquet-induced ischaemia.10,23 Clinically relevant conclusions are difficult to draw from animal studies because small animals have a different muscle fibre composition and vulnerability than humans.24

Nerves

Temporary nerve injuries may be underdiagnosed because of limb weakness postoperatively, as well as rapid recovery of the nerve. Reports of temporary or persistent nerve palsies and functional sequelae are uncommon in the literature, but nerve injuries do occur, especially at higher pneumatic tourniquet cuff pressures and after prolonged tourniquet inflation.25,26 According to the literature, the risk of nerve injury varies between 0.1 and 7.7%.26–28 Tourniquet-induced neurological injuries caused by shearing forces secondary to compression are more common than those resulting from ischaemia.29,30 In most cases of nerve injury, the damage occurs to the section of nerve directly under and near the edges of the cuff, and is associated with myelin disturbance and displacement of the nodes of Ranvier.31 A recent volunteer study showed that directly compressing a nerve causes focal ischaemia, inducing a localised axonal depolarisation, followed by hyperpolarisation upon release of compression.32 Hyperkalemia also reduces the transaxonal potassium currents. A short duration (4–13 min) of compression is sufficient to impair the transmission of stimuli and cutaneous afferents.33 Electromyography abnormalities have been noted during and after tourniquet use and may persist for up to 6 months afterwards.34

Tourniquet pain can be explained by ischaemia and compression, but it is increased with hyperalgesia phenomena (for example, when a traumatic injury is a primary stimulating factor).35 Thus, in addition to localised mechanisms, sensitisation of the central nervous system may also play a part in the tourniquet pain process. Evidence of expansion of the spinal receptive field of nociceptor neurons in response to tourniquet pain has been seen in animal studies.36 The pain tolerance in volunteer studies is approximately 20–30 min.16,37 In the absence of regional or general anaesthesia, topical application of a eutectic mixture of lidocaine–prilocaine (EMLA) cream (Astra Zeneca, London, UK) is as effective as circumferential subcutaneous anaesthesia in the reduction of tourniquet pain.38,39 Morphine added to a lidocaine epidural solution during regional anaesthesia significantly delays the onset of tourniquet pain.40

Vessels

Tourniquet use may damage intravascular endothelium. Arterial complications after total knee arthroplasty are rare, but the consequences can be disastrous (vascular reconstruction or amputation), particularly in the presence of peripheral arterial disease or ipsilateral peripheral arterial reconstruction.41 Careful monitoring of the vascular status of the limb is required in the early postoperative period to detect any vascular compromise.

Ischaemia and reperfusion effects

Duration of ischaemia

The ‘safe’ duration of tourniquet-induced ischaemia remains controversial.41 The maximum recommended period of tourniquet-induced ischaemia is 1 h.4,5,42 However, it has also been demonstrated that 3 h of continuous ischaemia will not produce irreversible damage in healthy muscle, although it will result in widespread sublethal injury to cells.43 After 1 h, it is common practice to deflate the tourniquet intermittently in an attempt to minimise the ischaemic damage.4 Reperfusion periods can be initiated within 45–60 min of ischaemia and must be at least 10 min to be beneficial. Reperfusion initiated after 2 h of ischaemia tends to exacerbate muscle injury.5 Beyond 60–90 min of ischaemia, the pathophysiological processes and inflammatory cascade are greater than the biological mechanisms of protection and brief periods of reperfusion are associated with a worsening of the injury rather than decreasing it.

Effects of reperfusion

Tourniquet release is associated with an immediate 10% increase in limb girth due to refilling of the vessels and hyperaemia. This causes an increase in intracompartmental pressure in the reperfused limb. Over the first postoperative day, the initial limb girth can increase by 50%.44 Swelling can remain significant for 6 weeks postoperatively.44 Releasing the tourniquet prior to haemostasis and closure reduces inflation time, allowing for a period of reperfusion and swelling before bandage or cast application. This may reduce complications associated with an increase in intracompartmental pressure compared with applying the dressing before tourniquet release. Deflation should be quick to prevent capillary bleeding. Just after the deflation, anaesthetic drugs sequestered in the exsanguinated limb are released and may be detected in some patients or when the bispectral index is used.45,46 This may be important in elderly or debilitated patients.47

Ischaemia–reperfusion results in a complex cascade of responses that can lead to muscle degeneration and loss of function. Despite the frequent use of tourniquets during limb surgery, it remains difficult to identify manifestations of ischaemia–reperfusion in humans, but effects have been seen in animal models.48 Signs of primary injury (vasodilatation and erythema) have been observed immediately after 1 h of tourniquet use. Secondary injury presents as a progression of cell injury despite reperfusion, which can end in a ‘no-reflow phenomenon’, when blood flow does not return to all areas after a long period of ischaemia. Leucocytes play a significant role in this phenomenon with adhesion in postcapillary venules, microvascular barrier disruption and oedema formation.48

Described in 1951, the ‘post-tourniquet syndrome’ combines weakness, stiffness, oedema, dysaesthesia and pain. These symptoms may be wrongly attributed to surgical trauma or to lack of patient motivation.4

Wound infection

The risk factors for infectious complications of arthroscopy include prolonged tourniquet inflation time.49 The systemic inflammatory response to tourniquet use may be explained by profound and sustained endothelial dysfunction and neutrophil activation.42 Wound hypoxia during lower limb orthopaedic surgery is also greater with tourniquet use than without.50,51 This may be relevant to wound healing and infection. Tourniquets (and exsanguinators) can also be a source of infection.52,53 Parenteral prophylactic antibiotics must be administered 10–20 min before tourniquet inflation and isolation of the operative site from the systemic circulation. After inflation of the tourniquet, antibiotics may not reach the exsanguinated limb. If the tourniquet has been inflated, regional intravenous injection of an antibiotic is a good alternative.54 However, antibiotic administration 10 min before the tourniquet release seems to be as effective as before inflation.55

Muscle

Skeletal muscle may be severely affected, even during relatively short periods of tourniquet use.48,56 Functional muscle loss seems to be worse if there is haemorrhage before tourniquet application.57 After anterior cruciate ligament reconstruction, the amount of vastus muscle amyotrophy after tourniquet use is significantly greater than that without tourniquet use.58,59 Cases of rhabdomyolysis with acute renal failure and compartment syndrome have been reported after tourniquet duration of more than 4 h but also with shorter inflation times (45–120 min).60,61 Interestingly, loss of strength,40 or electromyographic abnormalities,62 can also be observed in the contralateral limb, suggesting a sensitisation of the central nervous system.

The mechanism of muscle damage due to ischaemia and subsequent reperfusion is well understood. Complement activation, mast cell degranulation, neutrophil adhesion and infiltration, and microvascular dysfunction all play a role. During ischaemia, a cascade of ATP depletion, acidosis and ion imbalance occurs. The production of cytokines, reactive oxygen species and rapid calcium influx into the cells, which occurs progressively during reperfusion,63 is more damaging and causes mitochondrial dysfunction that leads to cellular apoptosis and necrosis.64 This does not seem to affect the contralateral side.65

Muscle injury seems to be greater in older patients, probably due to a greater susceptibility of aged skeletal muscle to ischaemia–reperfusion injury and to local attenuation of insulin-like growth factor-1 gene expression, which reduces regenerative mechanisms.66

Nerves

Limb dysfunction during ischaemia and reperfusion may be largely the result of axonal or neuromuscular junction injury, or both.48 After tourniquet deflation, a warming sensation, quickly turning into an aching sensation of burning, is associated with limb reperfusion.16,37 During reperfusion, the hyperaemic flow response in nerves is more prolonged than that in muscle.26,28 The factors that incite the ischaemic nerves to spontaneously discharge and cause paraesthesias upon reperfusion are not known.

Postoperative pain control is important for optimal functional recovery from surgery.44,67 Pain scores are often similar or lower in orthopaedic patients without tourniquet use.44,68 In order to reduce pain following arthroscopy, intra-articular injection of local anaesthetics must be performed either 10 min before tourniquet deflation, to allow fixation of local anaesthetics before the washout period, or 30 min after deflation.69,70

Vessels

The risk of DVT is significantly increased with a tourniquet time of more than 60 min.60 Following knee arthroscopy, the incidence of DVT diagnosed using contrast venography is approximately 18% 1 week after surgery.71 The formation of a DVT begins during tourniquet inflation and continues after deflation due to an increase in circulating markers of thrombosis (plasma D-dimer, tissue plasminogen activator, angiotensin-converting enzyme, antithrombin-III and protein C).72–74 Inflammation and haemostasis are linked by common activation pathways and feedback regulation. Tourniquet use exaggerates these responses, which peak on pneumatic tourniquet deflation and remain elevated on postoperative days 1 and 2.75–77

Systemic effects

In randomised studies, tourniquet use during knee replacement surgery does not reduce total blood loss.78,79 A meta-analysis of such surgery confirms that there is an initial increase in blood loss in groups without tourniquet use, but no difference in total blood loss or transfusion in comparison with patients in whom a tourniquet was used.1 An increase in local fibrinolysis postoperatively after tourniquet deflation, secondary to release of fibrinolytic factors from the surgical site, may explain the increased risk of bleeding into the joint or drains.80–83 The benefit of surgical haemostasis after tourniquet deflation is still under debate due to the risk of increased blood loss, but prospective studies support this.84,85

Cardiovascular effects

Tourniquet application has significant effects on the cardiovascular system. The mean arterial pressure increases progressively after inflation secondary to pain.86 Regional anaesthesia is better than general anaesthesia for moderating the cardiovascular response to tourniquet pain.86 Preoperative intravenous injection of a small dose of ketamine,87,88 dexmedetomidine,89 magnesium sulphate,90 oral dextromethorphan91 or clonidine92 can reduce the increase in systolic arterial pressure associated with inflation, reflecting an analgesic effect.

A brief period of hypotension upon deflation, secondary to metabolic and lactic acidosis and hyperkalaemia, can cause myocardial depression and even cardiac arrest in elderly or debilitated patients after prolonged lower limb surgery.93 Hypovolaemia may be observed after tourniquet deflation, due in part to haemorrhage at the surgical site but mostly to a combination of reactive vasodilatation and increased microvascular permeability in the reperfused limb during the first hour.

Pulmonary effects

Fatal or near-fatal pulmonary embolism was first reported after use of the Esmarch bandage and tourniquet inflation in orthopaedic surgery and was subsequently reported after tourniquet deflation.94–96 A significant correlation was noted between the occurrence of emboli and the duration of tourniquet application.78 Emboli occur during pneumatic tourniquet inflation and femur reaming in 27% of patients and in all patients after tourniquet deflation.82,88 Pulmonary embolism during orthopaedic surgery can result from fat embolism due to invasion of the medullary cavity.96,97 Air and cement emboli have also been reported after tourniquet release.98 The occurrence of emboli in patients undergoing invasive surgery (for example, knee replacement surgery) may be more frequent compared with non-invasive surgery (such as diagnostic arthroscopy).99 Even in the absence of a patent foramen ovale, cerebral microemboli frequently occur (60%) upon tourniquet release (probably through the opening of recruitable pulmonary vessels).100,101

Acute lung injury can be observed after limb reperfusion, with increased microvascular permeability, sequestration of neutrophils, and generation of oxygen-free radicals.77 Powerful neutrophil activation causes oxidative stress and has been used in an animal model to develop ‘tourniquet shock’ by applying two tourniquets simultaneously to both lower limbs of an animal.5

Neurological effects

Tourniquet deflation may be accompanied by a dangerous increase in intracranial pressure due to a simultaneous increase in carbon dioxide and a decrease in the systemic blood pressure upon release of the tourniquet. This could lead to a severe reduction in cerebral perfusion pressure with potentially disastrous consequences in patients with brain injuries.102 When propofol or sevoflurane (but not isoflurane) is used to maintain anaesthesia, hyperventilation after tourniquet deflation to minimise hypercapnia can prevent an increase in cerebral perfusion pressure.103

Treatment of ischaemia–reperfusion injury

New treatments have been proposed to help prevent or reduce the effects of ischaemia–reperfusion. Ischaemic preconditioning, defined as a brief period of ischaemia followed by tissue reperfusion (three or four cycles of 5 min of ischaemia with a cuff placed around the ipsilateral or contralateral arm or leg, followed by a 5 min of reperfusion) immediately before the clinical use of the tourniquet can be used to decrease the systemic effects of ischaemia–reperfusion after tourniquet use on upper or lower limbs, including attenuation of pulmonary dysfunction.104–107 Nitric oxide synthase and heme oxygenase have been implicated in this process.108,109 Ischaemic preconditioning of limbs also has anti-inflammatory effects on remote organs.110,111

Experimentally, ischaemic postconditioning, with intermittent repetitive interruptions to reperfusion after a prolonged period of ischaemia, has been found to be comparable with ischaemic preconditioning with regard to neuroprotective effects on spinal cord ischaemia.112 Interestingly, preconditioning and postconditioning can be applied on the contralateral limb with a significant effect on vascular endothelium dysfunction (vasoconstriction and thrombosis).110 These effects can be partially explained by humoral factors or neurologic pathways.

Prostaglandin analogues do not seem to reduce muscle injury.113 Antioxidants have a cytoprotective effect that could be attributed to inhibition of neutrophil adherence activation and scavenging of superoxide radicals.114,115 In humans, inhaled nitric oxide before, during and after the tourniquet application reduces inflammation in lower limb extremities.116,117 Heme oxygenase, which catalyses the breakdown of heme to iron, biliverdin IXa, and carbon monoxide may also be beneficial (carbon monoxide has a very similar action to nitric oxide).108 Administration of an endothelial xanthine oxidase inhibitor (allopurinol) or a radical scavenger such as vitamin E can decrease oxidative stress and oedema in postischaemic skeletal muscle.5 Another free radical scavenger (edaravone) given during early reperfusion seems to be effective in reducing nerve injury due to oxidative stress.118 To reduce microvascular reperfusion injury following tourniquet ischaemia in striated muscle, buflomedil or flurbiprofen can also be used.119

Local hypothermia using cold gel packs reduces metabolic demand by reducing ischaemic and anoxic degeneration, but, although it could be effective during ischaemia, it may aggravate injury after reperfusion.92,120

Phosphodiesterase-3 inhibitors can be used as inodilators (positive inotropes and arteriovenous dilators) to reduce DVT. A peri-operative infusion of milrinone can significantly attenuate platelet activation and monocyte tissue factor expression during knee replacement surgery without increasing peri-operative blood loss.121 Regional limb heparinisation is not effective in reducing the embolic phenomena after pneumatic tourniquet release.96 It is difficult to recommend the use of a particular technique to reduce ischaemia–reperfusion injury as none are in routine clinical use at this time. Preconditioning and postconditioning are easy to apply and can be performed when the tourniquet time is predicted to be more than (or is more than) 2–3 h.

Conclusion

The variable quality of the articles reviewed makes it difficult to establish an overview of the existing evidence on pneumatic tourniquet use, but the basic science confirms that there are transient changes attributable to its use. In practice, the tourniquet is a useful tool for good visualisation for extremity surgery, but it carries a risk of adverse effects. If the main indication is obtaining a good surgical visualisation (for example, in microsurgery), it should not be based just on haemostasis; a step-by-step haemostasis and pharmacological vasoconstriction may be used easily to obtain a bloodless field. Several relative contraindications to the use of a tourniquet have been described in the literature, including severe atherosclerotic disease, severe crush injuries, diabetes mellitus, sickle-cell disease and severe brain injury.5 Proven or suspected DVT, presence of calcified vessels, rheumatoid arthritis and other collagen-vascular diseases associated with vasculitis, as well as localised tumours, are also relative contraindications.4

To minimise adverse effects, the tourniquet must be used within the framework of strict procedures and protocols, with well adapted and regularly checked equipment. The location of the tourniquet must be as distal as is surgically possible. The AOP must be measured, and the tourniquet inflated to an AOP and 50–75 mmHg (or 75–100 mmHg greater than the SBP). The duration of tourniquet use should, ideally, be less than 1 h. Reperfusion periods can be initiated after 45–60 min of ischaemia for longer tourniquet times. To keep the duration of ischaemia as short as possible, tourniquet deflation prior to haemostasis and closure is preferable. After deflation, monitoring of the vascular and neurological status of the limb must be performed regularly and a temporary bandage or split plaster cast should be used for the first 2 days to allow for swelling and evaluation.

Acknowledgements

No financial support or sponsorship is declared. The authors declare no conflicts of interest.

References

1 Smith TO, Hing CB. Is a tourniquet beneficial in total knee replacement? A meta-analysis and systematic review. Knee 2010; 17:141–147.
2 Smith TO, Hing CB. A meta-analysis of tourniquet assisted arthroscopic knee surgery. Knee 2009; 16:317–321.
3 Smith TO, Hing CB. The efficacy of tourniquet in foot and ankle surgery? A systematic review and meta-analysis. Foot Ankle Surg 2010; 16:3–8.
4 Estebe JP. The pneumatic tourniquet. Surgical techniques in orthopaedics and traumatology (EFORT). In: DuParc J, editor. Elsevier; 2002.
5 Estebe JP, Mallédant Y. Pneumatic tourniquets in orthopedics. Ann Fr Anesth Reanim 1996; 15:162–178.
6 Lu CW, Chen YS, Wang MJ. Massive pulmonary embolism after application of Esmarch bandage. Anesth Analg 2004; 98:1187–1189.
7 Blønd L, Jensen NV, Søe Nielsen NH. Clinical consequence of different exsanguination methods in hand surgery: a double-blind randomized study. J Hand Surg Eur Vol 2008; 33:475–477.
8 Blønd L, Madsen L. Bone narrow perfusion in healthy subjects assessed by scintigraphy after application of a tourniquet. Acta Orthop Scand 2003; 74:460–464.
9 Crenshaw A. Surgical techniques and approaches. 9th ed. In: Campbell's operative orthopaedics. Volume 1. Canale ST, Jones L, editors. St Louis: Mosby; 1998. pp. 29–142.
10 Pedowitz RA, Gershuni DH, Schmidt AH, et al. Muscle injury beneath and distal to a pneumatic tourniquet: a quantitative animal study of effects of tourniquet pressure and duration. J Hand Surg Am 1991; 16:610–621.
11 Younger AS, McEwen JA, Inkpen K. Wide contoured thigh cuffs and automated limb occlusion measurement allow lower tourniquet pressures. Clin Orthop Relat Res 2004; 428:286–293.
12 Graham B, Breault MJ, McEwen JA, et al. Occlusion of arterial flow in the extremities at subsystolic pressures through the use of wide tourniquets cuffs. Clin Orthop Relat Res 1993; 286:257–261.
13 Reilly CW, McEwen JA, Leveille L, et al. Minimizing tourniquet pressure in paediatric anterior cruciate ligament reconstruction surgery: a blinded, prospective randomized controlled trial. J Pediatr Orthop 2009; 29:275–280.
14 Ishii Y, Noguchi H, Takeda M. Clinical use of a new tourniquet system for foot and ankle surgery. Int Orthop 2010; 34:355–359.
15 Tuncali B, Karci A, Tuncali BE, et al. A new method for estimating arterial occlusion pressure in optimizing pneumatic tourniquet inflation pressure. Anesth Analg 2006; 102:1752–1757.
16 Estebe JP, Le Naoures A, Chemaly L, et al. Tourniquet pain in a volunteer study: effect of changes in cuff width and pressure. Anaesthesia 2000; 55:21–26.
17 Mittal P, Shenoy S, Sandhu J. Effect of different cuff widths on the motor nerve conduction of the median nerve: an experimental study. J Orthop Surg Res 2008; 9:1–6.
18 McEwen JA, Kelly DL, Jardanowski T, et al. Tourniquet safety in lower leg applications. Orthop Nurs 2002; 21:55–62.
19 Pedowitz RA, Gershuni DH, Botte MJ, et al. The use of lower tourniquet inflation pressures in extremity surgery facilitated by curved and wide tourniquets and an integrated cuff inflation system. Clin Orthop Relat Res 1993; 287:237–244.
20 Olivecrona C, Tidermark J, Hamberg P, et al. Skin protection underneath the pneumatic tourniquet during total knee arthroplasty: a randomized controlled trial of 92 patients. Acta Orthop 2006; 77:519–523.
21 Hubik DJ, Connors A, Cleland H. Iatrogenic chemical burns associated with tourniquet use and prep solution. ANZ J Surg 2009; 79:762.
22 Chiang YC, Lin TS, Yeh MC. Povidone-iodine-related burn under the tourniquet of a child: a case report and literature review. J Plast Reconst Aesthet Surg 2011; 64:412–415.
23 Jacobson MD, Pedowitz RA, Oyama BK, et al. Muscle functional deficits after tourniquet ischemia. Am J Sports Med 1994; 22:372–377.
24 Walters TJ, Kragh JF, Baer DG. Influence of fiber-type composition on recovery from tourniquet-induced skeletal muscle ischemia-reperfusion injury. Appl Physiol Nutr Metabol 2008; 33:272–281.
25 Kornbluth I, Freedman MK, Sher L, et al. Femoral, saphenous nerve palsy after tourniquet use: a case report. Arch Phys Med Rehabil 2003; 84:909–911.
26 Horlocker TT, Hebl JR, Gali B, et al. Anesthetic, patient, and surgical risk factors for neurologic complications after prolonged total tourniquet time during total knee arthroplasty. Anesth Analg 2006; 102:950–955.
27 Odinsson A, Finsen V. Tourniquet use and its complications in Norway. J Bone Joint Surg Br 2006; 88:1090–1092.
28 Jacob AK, Mantilla CB, Sviggum HP, et al. Perioperative nerve injury after total knee arthroplasty: regional anesthesia risk during a 20-year cohort study. Anesthesiology 2011; 114:311–317.
29 Nitz AJ, Dobner JJ. Upper extremity tourniquet effects in carpal tunnel release. J Hand Surg Am 1989; 14:499–504.
30 Dobner JJ, Nitz AJ. Postmeniscectomy tourniquet palsy and functional sequelae. Am J Sports Med 1982; 10:211–214.
31 Noordin S, McEwen JA, Kragh JF, et al. Surgical tourniquets in orthopaedics. J Bone Joint Surg Am 2009; 91:2958–2967.
32 Ikemoto T, Tani T, Taniguchi S, et al. Effects of experimental focal compression on excitability of human median motor axons. Clin Neurophysiol 2009; 120:342–347.
33 Schlee G, Milani TL, Sterzing T, et al. Short-time lower leg ischemia reduces plantar foot sensitivity. Neurosci Lett 2009; 462:286–288.
34 Kokki H, Vääatäinen U, Miettinen H, et al. Tourniquet-induced changes in arthroscopic anterior cruciate ligament reconstruction: a comparison of low and high-pressure tourniquet systems. Ann Chir Gynaecol 2000; 89:313–317.
35 Byas-Smith MG, Bennett GJ, Gracely RH, et al. Tourniquet constriction exacerbates hyperalgesia-related pain induced by intradermal capsaicin injection. Anesthesiology 1999; 91:617–625.
36 Crew JC, Cahall MA. An investigation of the neurophysiologic mechanisms of tourniquet-related pain: changes in spontaneous activity and receptive field size in spinal dorsal horn neurons. Reg Anesth Pain Med 1999; 24:102–109.
37 Prodhomme G, Mouraux D, Dugailly PM, et al. Tolerance of upper extremity pneumatic tourniquets and their effect on grip strength. J Hand Surg Eur Vol 2008; 33:266–271.
38 Inal S, Er M, Ozsoy M, et al. Comparison of two anesthesia techniques for tourniquet pain with the use of forearm tourniquet. Iowa Orthop 2009; 29:55–59.
39 Tschaikowsky K, Hemmerling T. Comparison of the effect of EMLA and semicircular subcutaneous anaesthesia in the prevention of tourniquet pain during plexus anaesthesia of arm. Anaesthesia 1998; 53:390–393.
40 Cherng CH, Wong CS, Chang FL, et al. Epidural morphine delays the onset of tourniquet pain during epidural lidocaine anesthesia. Anesth Analg 2002; 94:1614–1616.
41 Wakai A, Winter DC, Street JT, et al. Pneumatic tourniquet in extremity surgery. J Am Acad Orthop Surg 2001; 9:345–351.
42 Ostman B, Michaelsson K, Rahme H, et al. Tourniquet-induced ischemia and reperfusion in human skeletal muscle. Clin Orthop Relat Res 2004; 418:260–265.
43 Day RL, Zale BW. The effect of tourniquets on muscle enzymes during foot and ankle surgery. J Foot Ankle Surg 1993; 32:280–285.
44 Konrad G, Markmiller M, Lenich A, et al. Tourniquets may increase postoperative swelling and pain after internal fixation of ankle fractures. Clin Orthop Relat Res 2005; 433:189–194.
45 Estebe JP, Le Corre P, Levron JC, et al. Pilot study on the effect of tourniquet on sufentanil pharmacokinetics. J Clin Anesth 2002; 14:578–583.
46 Shimogai M, Iranami H, Yamazaki A, et al. Transient but profound reduction of bispectral index values after tourniquet deflation: did the BIS detect an alteration of brain electrocortical activity? Anesth Analg 2006; 103:1613–1614.
47 Schmitt H, Batz G, Knoll R, et al. Plasma level changes of fentanyl and midazolam after release of a prolonged thigh tourniquet. Acta Anaesthesiol Scand 1990; 34:104–108.
48 Blaisdell FW. The pathophysiology of skeletal muscle ischemia and reperfusion syndrome: a review. Cardiovasc Surg 2002; 10:620–630.
49 Babcock HM, Matava MJ, Fraser V. Postarthroscopy surgical site infections: review of the literature. Clin Infect Dis 2002; 34:65–71.
50 Clarke MT, Longstaff L, Edwards D, et al. Tourniquet-induced wound hypoxia after total knee replacement. J Bone Joint Surg Br 2001; 83:40–44.
51 Maffulli N, Testa V, Capasso G. Use of tourniquet in the internal fixation of fractures of the distal part of the fibula: a prospective randomized trial. J Bone Joint Surg Am 1993; 75:700–703.
52 Brennan SA, Walls RJ, Smyth E, et al. Tourniquets and exsanguinators: a potential source of infection in the orthopedic operating theater? Acta Orthop 2009; 80:251–255.
53 Ahmed SM, Ahmad R, Case R, et al. A study of microbial colonization of orthopaedic tourniquets. Ann R Coll Surg Engl 2009; 91:131–134.
54 Gilliam JN, Streeter RN, Papich MG, et al. Pharmacokinetics of florfenicol in serum and synovial fluid after regional intravenous perfusion in the distal portion of the hind limb of adult cows. Am J Vet Res 2008; 69:997–1004.
55 Soriano A, Bori G, Garcia-Ramiro S, et al. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed during ischemia. Clin Infect Dis 2008; 46:1009–1014.
56 Pedowitz RA. Tourniquet-induced neuromuscular injury. A recent review of rabbit and clinical experiments. Acta Orthop Scand 1991; 245:1–33.
57 Walters TJ, Kragh JF, Kauvar DS, et al. The combined influence of hemorrhage and tourniquet application on the recovery of muscle function in rats. J Orthop Trauma 2008; 22:47–51.
58 Nicholas SJ, Tyler TF, McHugh MP, et al. The effect on leg strength of tourniquet use during anterior cruciate ligament reconstruction: a prospective randomized study. Arthroscopy 2001; 17:603–607.
59 Kirkley A, Rampersaud R, Griffin S, et al. Tourniquet versus no tourniquet use in routine knee arthroscopy: a prospective, double-blind, randomized clinical trial. Arthroscopy 2000; 16:121–126.
60 Sheth NP, Sennett B, Berns JS. Rhabdomyolysis and acute renal failure following arthroscopic knee surgery in a college football player taking creatine supplements. Clin Nephrol 2006; 65:134–137.
61 Lee YG, Park W, Kim SH, et al. A case of rhabdomyolysis with use of a pneumatic tourniquet during arthroscopic knee surgery. Kor J Int Med 2010; 25:105–109.
62 McNulty PA, Macefield VG, Taylor JL, et al. Cortically evoked neural volleys to the human hand are increased during ischaemic block of the forearm. J Physiol 2002; 538:279–288.
63 Carmo-Araújo EM, Dal-Pai-Silva M, Dal-Pai V, et al. Ischaemia and reperfusion effects on skeletal muscle tissue: morphological and histochemical studies. Int J Exp Pathol 2007; 88:147–154.
64 Honda HM, Korge P, Weiss JN. Mitochondria and ischemia/reperfusion injury. Ann NY Acad Sci 2005; 1047:248–258.
65 Thaveau F, Zoll J, Bouitbir J, et al. Contralateral leg as a control during skeletal muscle ischemia-reperfusion. J Surg Res 2009; 155:65–69.
66 Hammers DW, Merritt EK, Matheny W, et al. Functional deficits and insulin-like growth factor-I gene expression following tourniquet-induced injury of skeletal muscle in young and old rats. J Appl Physiol 2008; 105:1274–1281.
67 Kawamura N, Schmeichel AM, Wang Y, et al. Multiple effect of hypothermia on inflammatory response following ischemia-reperfusion injury in experimental ischemic neuropathy. Exp Neurol 2006; 202:487–496.
68 Wakankar HM, Nicholl JE, Koka R, et al. The tourniquet in total knee arthroplasty: a prospective randomised study. J Bone Joint Surg Br 1999; 81:30–33.
69 Guler G, Karaoglu S, Akin A, et al. When to inject analgesic agents intra-articularly in anterior cruciate ligament reconstruction: before or after tourniquet releasing. Arthroscopy 2004; 20:918–921.
70 Gomoll AH, Yanke AB, Kang RW, et al. Long-term effects of bupivacaine on cartilage in a rabbit shoulder model. Am J Sports Med 2009; 37:72–77.
71 Demers C, Marcoux S, Ginsberg JS, et al. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med 1998; 158:47–50.
72 Nishiguchi M, Takamura N, Abe Y, et al. Pilot study on the use of tourniquet: a risk factor for pulmonary thromboembolism after total knee arthroplasty. Thromb Res 2005; 115:271–276.
73 Jules-Elysee K, Blanck T, Catravas J, et al. Angiotensin-converting enzyme activity: a novel way of assessing pulmonary changes during total knee arthroplasty. Anesth Analg 2004; 99:1018–1022.
74 Reikeras O, Clementsen T. Thrombosis markers in hip versus knee arthroplasty: a pilot study. J Orthop Surg (Hong Kong) 2009; 17:291–295.
75 Kageyama K, Nakajima Y, Shibasaki M, et al. Increased platelet, leukocyte, and endothelial cell activity are associated with increased coagulability in patients after knee arthroplasty. J Thromb Haemost 2007; 5:738–745.
76 Johnson GJ, Leis LA, Bach RR. Tissue factor activity of blood mononuclear cells increased after total knee arthroplasty. Thromb Haemost 2009; 102:728–734.
77 Katsumata S, Nagashima M, Kato K, et al. Changes in coagulation-fibrinolysis marker and neutrophil elastase following the use of tourniquet during total knee arthroplasty and influence of neutrophil elastase on thromboembolism. Acta Anaesthesiol Scand 2005; 49:510–516.
78 Iorio R, Healy WL. Tourniquet use during total knee arthroplasty did not reduce total blood loss. J Bone Joint Surg Am 2001; 83:1282.
79 Tetro AM, Rudan JF. The effects of a pneumatic tourniquet on blood loss in total knee arthroplasty. Can J Surg 2001; 44:33–38.
80 Aglietti P, Baldini A, Vena LM, et al. Effect of tourniquet on activation of coagulation in total knee replacement. Clin Orthop 2000; 371:169–177.
81 Li B, Wen Y, Wu H, et al. The effect of tourniquet use on hidden blood loss in total knee arthroplasty. Int Orthop 2009; 33:1263–1268.
82 Hirota K, Hashimoto H, Kabara S, et al. The relationship between tourniquet tine and pulmonary emboli in patients underground knee arthroscopic surgeries. Anesth Analg 2001; 93:776–780.
83 Padala PR, Rouholamin E, Mehta RL. The role of drains and tourniquet in primary total knee replacement: a comparative study of TKR performed with drains and tourniquet versus no drains and adrenaline and saline infiltration. J Knee Surg 2004; 17:24–27.
84 Rama KR, Apsingi S, Poovali S, et al. Timing of tourniquet release in knee arthroplasty. Meta- analysis of randomized, controlled trials. J Bone Joint Surg Am 2007; 89:699–705.
85 Bell TH, Berta D, Ralley F, et al. Factors affecting perioperative blood loss and transfusion rates in primary total joint arthroplasty: a prospective analysis of 1642 patients. Can J Surg 2009; 52:295–301.
86 Valli H, Rosenberg PH, Kytta J, et al. Arterial hypertension associated with the use of tourniquet with either general or regional anaesthesia. Acta Anaesthesiol Scand 1987; 31:279–283.
87 Satsumae T, Yamaguchi H, Sakaguchi M, et al. Preoperative small-dose ketamine prevented tourniquet-induced arterial pressure increase in orthopedic patients under general anesthesia. Anesth Analg 2000; 92:1286–1289.
88 Kato N, Nakanishi K, Yoshino S, et al. Abnormal echogenic findings detected by transesophageal echocardiography and cardiorespiratory impairment during total knee arthroplasty with tourniquet. Anesthesiology 2002; 97:1123–1128.
89 Allee J, Muzaffar AR, Tobias JD. Dexmedetomidine controls the hemodynamic manifestation of tourniquet pain. Am J Ther 2011 [Epub ahead of print].
90 Lee DH, Jee DL, Kim SY, et al. Magnesium sulphate attenuates tourniquet-induced hypertension and spinal c-fos mRNA expression: a comparison with ketamine. J Int Med Res 2006; 34:573–584.
91 Yamashita S, Yamaguchi H, Hisajima Y, et al. Preoperative oral dextromethorphan attenuated tourniquet-induced arterial blood pressure and heart rate increases in knee cruciate ligament reconstruction patients under general anesthesia. Anesth Analg 2004; 98:994–998.
92 Honarmand A, Safavi MR. Preoperative oral dextromethorphan vs clonidine to prevent tourniquet-induced cardiovascular responses in orthopaedic patients under general anesthesia. Eur J Anaesthesiol 2007; 24:511–515.
93 Gupta K, Aggarwal N, Rao M, et al. Re-emphasizing the importance of tourniquet time: severe myocardial depression following tourniquet deflation. Acta Anaesthesiol Scand 2008; 52:873.
94 Darmanis S, Papanikolaou A, Pavlakis D. Fatal intra-operative pulmonary embolism following application of an Esmarch bandage. Injury 2002; 33:761–764.
95 Bharti N, Mahajan S. Massive pulmonary embolism leading to cardiac arrest after deflation following lower limb surgery. Anaesth Intensive Care 2009; 37:867–868.
96 Giachino AA, Rody K, Turek MA, et al. Systemic fat and thrombus embolization in patients undergoing total knee arthroplasty with regional heparinization. J Arthroplasty 2001; 16:288–292.
97 Watanabe S, Terazawa K, Matoba K, et al. An autopsy of intraoperative death due to pulmonary fat embolism: possibly caused by release of tourniquet after multiple muscle-release and tenotomy of bilateral lower limbs. Forensic Sci Int 2007; 171:73–77.
98 McGrath BJ, Hsia J, Boyd A, et al. Venous embolization after deflation of lower extremity tourniquets. Anesth Analg 1994; 78:349–353.
99 Hirota K, Hashimoto H, Tsubo T, et al. Quantification and comparison of pulmonary emboli formation after pneumatic tourniquet release in patients undergoing reconstruction of anterior cruciate ligament and total knee arthroplasty. Anesth Analg 2002; 94:1633–1638.
100 Sulek CA, Davies LK, Enneking K, et al. Cerebral microembolism diagnosed by transcranial Doppler during total knee arthroplasty: correlation with transesophageal echocardiography. Anesthesiology 1999; 91:672–676.
101 Wauke K, Nagashima M, Kato N, et al. Comparative study between thromboembolism and total knee arthroplasty with or without tourniquet in rheumatoid arthritis patients. Arch Orthop Trauma Surg 2002; 122:442–446.
102 Sparling RJ, Murray AW, Choksey M. Raised intracranial pressure associated with hypercarbia after tourniquet release. Br J Neurosurg 1993; 7:75–77.
103 Hinohara H, Kadoi Y, Ide M, et al. Differential effects of hyperventilation on cerebral blood flow velocity after tourniquet deflation during sevoflurane, isoflurane, or propofol anesthesia. J Anesth 2010; 24:587–593.
104 Eastlack RR, Groppo ER, Hargens AR, et al. Ischemic-preconditioning does not prevent neuromuscular dysfunction after ischemia reperfusion injury. J Orthop Res 2004; 22:918–923.
105 Kharbanda RK, Petres M, Walton B, et al. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation 2001; 103:1624–1630.
106 Van M, Olguner C, Koca U, et al. Ischaemic preconditioning attenuates haemodynamic response and lipid peroxidation in lower-extremity surgery with unilateral pneumatic tourniquet application: a clinical pilot study. Adv Ther 2008; 25:355–366.
107 Lin LN, Wang LR, Wang WT, et al. Ischemic preconditioning attenuates pulmonary dysfunction after unilateral thigh tourniquet-induced ischemia-reperfusion. Anesth Analg 2010; 111:539–543.
108 Dungey AA, Badhwar A, Bihari A, et al. Role of heme oxygenase in the protection afforded skeletal muscle during ischemic tolerance. Microcirculation 2006; 13:71–79.
109 Badhwar A, Bihari A, Dungey AA, et al. Protective mechanisms during ischemic tolerance in skeletal muscle. Free Radic Biol Med 2004; 36:371–379.
110 Loukogeorgakis SP, Williams R, Panagiotidou AT, et al. Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependant mechanism. Circulation 2007; 116:1386–1395.
111 Kanoria S, Jalan R, Davies NA, et al. Remote ischaemic preconditioning of the hind limb reduces experimental liver warm ischaemia-reperfusion injury. Br J Surg 2006; 93:762–768.
112 Jiang X, Ai C, Shi E, et al. Neuroprotection against spinal cord ischemia-reperfusion injury induced by different ischemic postconditioning methods: roles of phosphatidylinositol 3- kinase-Akt and extracellular signal-regulated kinase. Anesthesiology 2009; 111:1197–1205.
113 Antonio LG, Evora PR, Piccinato CE. Use of alprostadil, a stable prostaglandin E1 analogue, for the attenuation of rat skeletal muscle ischemia and reperfusion injury. Minerva Chir 2009; 64:559–564.
114 Arieli D, Nahmany G, Casap N, et al. The effect of nitroxide antioxidant on ischemia-reperfusion injury in the rat in vivo hind limb model. Free Radic Res 2008; 42:114–123.
115 Bolcal C, Yildrim V, Doganci S, et al. Protective effects of antioxidant medications on limb ischemia reperfusion injury. J Surg Res 2007; 139:274–279.
116 Mathru M, Huda R, Solanki DR, et al. Inhaled nitric oxide attenuates reperfusion inflammatory responses in humans. Anesthesiology 2007; 106:275–282.
117 Gabriel A, Porrino ML, Stephenson LL, et al. Effect of L-arginine on leukocyte adhesion in ischemia-reperfusion injury. Plastic Reconstr Surg 2004; 113:1698–1702.
118 Iida H, Nagasaka T, Shindo K, et al. Effect of the free radical scavenger edaravone on peripheral nerve ischemia-reperfusion injury. Muscle Nerve 2009; 40:582–588.
119 Tibrewal SB. The pneumatic tourniquet in arthroscopic surgery of the knee. Int Orthop 2001; 24:347–349.
120 Kawamura N, Schmelzer JD, Wang Y, et al. The therapeutic window of hypothermic neuroprotection in experimental ischemic neuropathy: protection in ischemic neuropathy and potential deterioration in later reperfusion phase. Exp Neurol 2005; 185:305–312.
121 Beppu S, Nakajima Y, Shibasaki M, et al. Phosphodiesterase 3 inhibition reduces platelet activation and monocyte tissue factor expression in knee arthroplasty patients. Anesthesiology 2009; 111:1227–1237.
Keywords:

bleeding; ischaemia–reperfusion; pneumatic tourniquet; pressure; thromboembolism

© 2011 European Society of Anaesthesiology